S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
NASDAQ:LMDX

LumiraDx (LMDX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.0076
$0.0160
52-Week Range
N/A
Volume
132.24 million shs
Average Volume
56.75 million shs
Market Capitalization
$5.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.75
LMDX stock logo

About LumiraDx Stock (NASDAQ:LMDX)

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.

LMDX Stock News Headlines

LumiraDx Ltd LMDXF
LMDX.O
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Why Is LumiraDx (LMDX) Stock Down 13% Today?
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
LumiraDx Agrees To Sell Point-of-Care Tech Platform To Roche
LumiraDx Limited (LMDX)
LumiraDx Ltd LMDX
See More Headlines
Receive LMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LumiraDx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/24/2023
Today
4/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LMDX
Fax
N/A
Employees
1,210
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.75
High Stock Price Target
$2.70
Low Stock Price Target
$0.80
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-447,790,000.00
Net Margins
-268.45%
Pretax Margin
-264.58%

Debt

Sales & Book Value

Annual Sales
$126.52 million
Book Value
($0.33) per share

Miscellaneous

Free Float
205,749,000
Market Cap
$5.10 million
Optionable
Not Optionable
Beta
1.73
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Ms. Veronique Ameye EMBA (Age 46)
    Esq., M.B.A., CEO & General Counsel
  • Mr. Dorian LeBlanc CPA (Age 48)
    CFO & VP of Global Operations
  • Ms. Colleen McMillen
    Vice President of Communications
  • Andy Ward
    National Sales Director - UK
  • Mr. David Walton DMS (Age 69)
    Chief Commercial Officer
  • Giffin Daughtridge
    President of North America Commercial Operations & Global Molecular Solutions
  • Melissa Garcia
    VP & Corporate Counsel

LMDX Stock Analysis - Frequently Asked Questions

Should I buy or sell LumiraDx stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LumiraDx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LMDX shares.
View LMDX analyst ratings
or view top-rated stocks.

What is LumiraDx's stock price target for 2024?

1 equities research analysts have issued 12 month price objectives for LumiraDx's stock. Their LMDX share price targets range from $0.80 to $2.70. On average, they expect the company's share price to reach $1.75 in the next twelve months.
View analysts price targets for LMDX
or view top-rated stocks among Wall Street analysts.

How were LumiraDx's earnings last quarter?

LumiraDx Limited (NASDAQ:LMDX) announced its earnings results on Thursday, August, 24th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.01. The firm earned $21 million during the quarter, compared to the consensus estimate of $21.07 million. During the same period in the previous year, the company earned ($0.58) earnings per share.

This page (NASDAQ:LMDX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners